Welcome to our dedicated page for Lisata Therapeutics news (Ticker: $LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lisata Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lisata Therapeutics's position in the market.
Lisata Therapeutics, Inc. reported strong first-quarter 2024 financial results and provided an update on its business activities. The company is anticipating pivotal data readouts from the Phase 2b ASCEND trial later in 2024, with transformative potential. They have received significant regulatory designations for their investigational drug certepetide in various cancer types. Lisata's financial management allows operations to be funded until early 2026. The company is executing multiple ongoing and planned clinical trials globally to advance their innovative therapies.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) will participate in several industry and investor events in May 2024, including the Pharma Partnering U.S. Summit, BioNJ BioPartnering Conference, Pharma Partnering EU Summit, 10th Annual Oncology Innovation Forum, and the 2024 ASCO Annual Meeting. The Company aims to showcase its innovative therapies for advanced solid tumors and serious diseases, with key representatives like Tariq Imam and David J. Mazzo presenting at these events.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) will release its financial results for the first quarter of 2024 on May 9, 2024. The company focuses on developing therapies for solid tumors and serious diseases. A conference call will follow the release, with a webcast available for replay on the company's website.